← All trials
NCT05003479
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2021
- Primary completion
- Sep 30, 2022
- Completion date
- Oct 31, 2022
- First posted
- Aug 12, 2021
- Last posted
- Aug 18, 2021
- Enrollment
- 84
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Shenzhen Kangtai Biological Products Co., LTDLead sponsor
- Beijing Minhai Biotechnology Co., LtdCollaborator
- Government of ChinaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.